These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6141721)

  • 21. Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension.
    Beretta-Piccoli C; Ferrier C; Weidmann P
    J Hypertens Suppl; 1985 Dec; 3(3):S231-4. PubMed ID: 2908818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacology of prazosin, an alpha 1-adrenoceptor antagonist and the basis for its use in the treatment of essential hypertension.
    Davey MJ
    Clin Exp Hypertens A; 1982; 4(1-2):47-59. PubMed ID: 6122521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Responsiveness of superficial hand veins to phenylephrine in essential hypertension. Alpha adrenergic blockade during prazosin therapy.
    Eichler HG; Ford GA; Blaschke TF; Swislocki A; Hoffman BB
    J Clin Invest; 1989 Jan; 83(1):108-12. PubMed ID: 2562959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypertension--drug management.
    Anand MP
    J Assoc Physicians India; 1982 Feb; 30(2):101-5. PubMed ID: 6132908
    [No Abstract]   [Full Text] [Related]  

  • 25. Alpha-adrenergic blockade in the treatment of essential hypertension.
    De Leeuw PW; Birkenhäger WH
    Neth J Med; 1983; 26(9):274-82. PubMed ID: 6140644
    [No Abstract]   [Full Text] [Related]  

  • 26. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
    MacCarthy EP; Bloomfield SS
    Pharmacotherapy; 1983; 3(4):193-219. PubMed ID: 6310529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
    Izzo JL; Licht MR; Smith RJ; Larrabee PS; Radke KJ; Kallay MC
    Am J Cardiol; 1987 Aug; 60(4):303-8. PubMed ID: 2887102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cardiovascular effects of alpha-receptor blocking agents.
    Leren P
    J Hypertens Suppl; 1992 Jun; 10(3):S11-4; discussion S14-5. PubMed ID: 1353110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.
    Lund-Johansen P
    Drugs; 1984; 28 Suppl 2():35-50. PubMed ID: 6151890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-blockers and converting enzyme inhibitors.
    Rubin PC; Reid JL
    Br Med J (Clin Res Ed); 1983 Apr; 286(6372):1192-5. PubMed ID: 6132654
    [No Abstract]   [Full Text] [Related]  

  • 31. Review of the use of alpha-adrenoceptor antagonists in hypertension.
    Stokes GS; Marwood JF
    Methods Find Exp Clin Pharmacol; 1984 Apr; 6(4):197-204. PubMed ID: 6146746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacological basis for the use of alpha 1-adrenoceptor antagonists in the treatment of essential hypertension.
    Davey MJ
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):5S-8S. PubMed ID: 2871856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic and therapeutic significance of alpha-adrenoceptor subtypes.
    Langer SZ; Duval N; Massingham R
    J Cardiovasc Pharmacol; 1985; 7 Suppl 8():S1-8. PubMed ID: 2417042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha 1-adrenergic receptor blockade reduces afferent and efferent glomerular arteriolar resistances in SHR.
    Uchino K; Nishikimi T; Frohlich ED
    Am J Physiol; 1991 Sep; 261(3 Pt 2):R576-80. PubMed ID: 1679607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential of alpha blockade in treating human hypertension: a role for indoramin.
    Laragh JH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S37-42. PubMed ID: 2423795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The alpha 1- and alpha 2-adrenoceptor selectivity of drugs with potential effects on blood pressure--a radioligand-binding study.
    Offermeier J; van Rooyen JM; Rossouw J
    S Afr Med J; 1986 Feb; 69(4):234-6. PubMed ID: 2869590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacotherapeutics of doxazosin.
    Taylor SH
    Am J Med; 1989 Aug; 87(2A):2S-11S. PubMed ID: 2569822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-adrenoreceptors in hypertension.
    Rosendorff C
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S3-7. PubMed ID: 2423793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical settings for selective alpha-adrenergic receptor inhibition: rationale and management strategies. Proceedings of a symposium. Naples, Florida, October 13 to 16, 1988.
    Am J Med; 1989 Aug; 87(2A):1S-66S. PubMed ID: 2569821
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.